Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
date Close change Change (%) instr__open High Low

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Latest news

Show more
Ghko B 2025 Jul 09, 16:00

Stock market today: Nasdaq rallied to new highs as Nvidia hits $4T valuation

Stocks Indices
Ghko B 2025 Jul 09, 16:00

Datadog (DDOG) Joins S&P 500: What’s the Datadog stock price target in 2025?

Stocks Indices
Frances Wang 2025 Jul 08, 16:00

DJT Stock News: Trump Media Plans to Bring Blue Chip Crypto ETF to Market

Stocks ETFs
Ghko B 2025 Jul 08, 16:00

Trump crypto portfolio: TRUMP meme coin, MELANIA coin, ETH, Chainlink

AAPL
Tommy Yap 2025 Jul 08, 16:00

Morning Note: RBNZ Holds; Yen Falls on Tariffs; Copper Surges on Tariffs

Morning Note Central Banks Forex Commodities
Tommy Yap 2025 Jul 07, 16:00

Morning Note: RBA Holds Rates; Trump Tariffs Hit; Tesla Dips on Musk News

Morning Note Stocks Central Banks
Frances Wang 2025 Jul 06, 16:00

Stock market today: Dow, S&P 500, Nasdaq futures fall, Sensex, Nifty update

Stocks Indices
Frances Wang 2025 Jul 06, 16:00

Lumber Stocks to Watch: SSD stock, UFPI stock, HD stock

Stocks

Info

Spread

0.7715

Spread (%)

0.6918 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Thursday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Friday

13:31-19:59

instr__analysis_statistics

instr__open

---

instr__close

---

instr__52week_range

--- – ---

instr__market_cap

26842507264

instr__shares_outstand

240395008

instr__earnings_date

0000-00-00

instr__dividend_date

2022-06-17

instr__ex_dividend_date

2022-06-02

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

instr__eps

-3.81

instrument_learn_more

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Markets.com Bonus Trading

related_instruments

Asset
Sell
Buy
Change (%)

trade_now_btn

trade_now_btn

trade_now_btn

trade_now_btn
view_all_instruments

latest_education_articles

Show more
Trustpilot